ESC-HFA 2023: Late-Breaking Science Video Collection
Published: 23 May 2023
-
Views:
3184
-
Likes:
7
-
Views:
3184
-
Likes:
7
-
Up Next -
8m 22sPart 2 | Session 9 Diagnosis in Heart Failure in Women -
3m 50sPart 2 | Session 10 Dapagliflozin and Peripheral Arterial Disease in Heart Failure
-
26m 30sPart 1 | Session 1 Hospital to Home in HF: Insights from ACT-HF, PROMPT-AHF & STRONG-HF Kidney Harriette Van Spall, Tariq Ahmad, Jozine ter Maaten
-
5m 48sPart 1 | Session 2 The PARAGLIDE-HF Trial Harriette Van Spall, Robert Mentz
-
13m 32sPart 1 | Session 3 HFA 2023 Late-breaking Science Highlights With Dr Van Spall & Dr Januzzi Harriette Van Spall, James L Januzzi
-
4m 3sPart 1 | Session 4 TRACER-HF: Trientine-HCL for Treatment of Heart Failure and Reduced Ejection Fraction James L Januzzi, Harriette Van Spall
-
2m 45sPart 2 | Session 1 MONITOR-HF: Improving QoL& Reducing HF Hospitalisations with PAP Monitoring Jasper J Brugts
-
6m 54sPart 2 | Session 2 REDWOOD-HCM-Cohort 4: Aficamten in Non-obstructive Hypertrophic Cardiomyopathy Ahmad Masri
-
3m 11sPart 2 | Session 3 APOLLO-B: Patisiran Treatment for Cardiac Amyloidosis Marianna Fontana
-
4m 45sPart 2 | Session 4 DAPA-HF and DELIVER: KCCQ in Patients with Varying Ejection Fraction Ankeet Bhatt
-
8m 47sPart 2 | Session 5 DAPA MODA: Dapaglifozin & Cardiac Remodelling in Chronic HF Domingo Figal
-
4m 53sPart 2 | Session 6 NUDGE-FLU: Increasing Influenza Vaccination in HF Patients Niklas Dyrby Johansen
-
3m 56sPart 2 | Session 7 DAPA-RESIST: Dapagliflozin Vs Metolazone in Diuretic-Resistant HF Ross Campbell
Overview
Get the most out of the new data from, Late-breaker host, Dr Harriette Van Spall and Dr James Januzzi wrap up of the most impactful trials and studies presented at Heart Failure 2023.
Delve into in-depth and critical discussions with Dr Van Spall in our thought-provoking Late-breaker Discussion series.
For concise and practical take-home messages for practice and cardiovascular research watch our 5-minute Expert Interviews conducted with investigators.
Watch our Behind the Heart Series to hear more from the personal perspectives of the investigators behind the top trials of HFA 2023.
More from this programme
Part 1
Late-breaker Discussions with Dr Van Spall
Part 2
Expert Interviews
About the episode
Dr Stephen Greene (Duke University School of Medicine, US) outlines the findings from the QoL study of the TRANSFORM-HF Trial.
The TRANSFORM-HF trial is a randomized trial which compared torsemide to furosemide as a treatment for patients with heart failure. Around 2859 patients with heart failure were enrolled in the trial, whose clinical outcomes were measured across 12 months. Patients were randomized in a 1:1 fashion, to receive either oral torsemide or oral furosemide. Results from the QoL suggest that among patients with HF, a routine strategy of prescribing torsemide versus furosemide did not meaningfully impact patient symptoms or quality of life over 12-month follow-up.
Interview Questions:
1. What is the background of this study?
2. How do torsemide and furosemide differ in terms of their mechanisms of action?
3. What was the rationale behind this QoL study?
4. What is the study design and patient population?
5. What data are you presenting at HFA 23?
6. Based on the results, what are the key messages?
7. What are the remaining unanswered questions regarding the choice of loop diuretic?
Faculty Biographies
Stephen J Greene
Assistant Professor, Division of Cardiology
Dr Greene is a cardiologist with a clinical and research interest in improving quality of care and outcomes for patients with heart failure. He has been a co-investigator and co-author of multiple national and international heart failure trials studying medical therapies for heart failure. He has also served on leadership committees and led multiple analyses from national and international heart failure registries characterising the quality of heart failure care. Dr Greene’s collaborative work has led to more than 350 publications in peer-reviewed journals.
Comments